Bexion Pharmaceuticals

What Bexion Pharmaceuticals does

Bexion Pharmaceuticals is a privately-held, clinical-stage biopharmaceutical company founded in 2006 and headquartered in Covington, Kentucky. The company's sole lead asset, BXQ-350, is a first-in-class biologic composed of the multifunctional sphingolipid activator protein Saposin C (an 80-amino acid human protein analog) embedded in vesicles of the phospholipid DOPS (Dioleoyl Phosphatidylserine). BXQ-350 allosterically activates multiple enzymes in sphingolipid metabolism, decreasing pro-tumor Sphingosine-1-Phosphate (S1P) and increasing pro-apoptotic ceramide, with additional activity in repolarizing tumor-associated macrophages toward an M1 phenotype, inhibiting MDSCs, and promoting NK and TIL activity. More than 2,000 patient doses have been administered across adult and pediatric Phase 1 trials with no DLT or MTD identified.

Bexion is advancing BXQ-350 across four primary clinical programs: a Phase 1b/2 study in newly diagnosed metastatic colorectal cancer (mCRC) in combination with mFOLFOX7 and bevacizumab (the ASIST study, NCT05322590); a proof-of-concept trial in chemotherapy-induced peripheral neuropathy (CIPN, NCT05291286); a completed Phase 1b pediatric trial in DIPG/DMG (NCT04771897); and a glioblastoma program supported by demonstrated blood-brain barrier penetration. Additional preclinical and grant-supported work targets neurodegenerative disease, including a Michael J. Fox Foundation grant awarded in November 2024 to explore Parkinson's disease applications. Clinical sites and patient enrollment are US-based only.

Bexion's business model is currently pre-revenue. The company does not sell any approved product; access to BXQ-350 is restricted to authorized clinical trial participants, and pricing has not been publicly disclosed. Revenue is expected upon regulatory approval and commercialization, and the company has signaled interest in partnership-driven commercialization via licensing. Go-to-market activity centers on scientific conference participation (ASCO, AACR, SITC, ESMO), healthcare investor conferences (Jefferies London Healthcare Conference), PRNewswire press releases, the company's investor website, and collaborations with patient advocacy organizations such as Cancer Support Community. The company has 11–50 employees and is anchored at the LifeSciKY innovation hub in Covington, KY.

Name

Bexion Pharmaceuticals

Legal name

Bexion Pharmaceuticals, Inc.

Website

https://bexionpharma.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Bexion Pharmaceuticals is a privately-held, clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class sphingolipid metabolism modulator (Saposin C in DOPS vesicles), for solid tumors including metastatic colorectal cancer and glioblastoma, chemotherapy-induced peripheral neuropathy, and pediatric DIPG/DMG.

Ownership category

akta.pro rank

Product category

Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Oncology drug development
• Cancer biologic therapy
• Sphingolipid metabolism modulation
• Chemotherapy-induced neuropathy
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Covington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical / Biologic Development: As a clinical-stage biopharmaceutical company, Bexion Pharmaceuticals does not yet have commercial revenue. The company is developing BXQ-350 as an investigational biologic therapy targeting solid tumors and CIPN. Revenue would be generated upon regulatory approval and commercialization of BXQ-350.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class biologic consisting of Saposin C (SapC) embedded in DOPS phospholipid vesicles. BXQ-350 modulates sphingolipid metabolism—lowering pro-tumor S1P and elevating pro-apoptotic ceramide—to treat solid tumors including metastatic colorectal cancer, glioblastoma, pediatric DIPG/DMG, and chemotherapy-induced peripheral neuropathy (CIPN). The investigational therapy is currently administered exclusively through authorized U.S. clinical trials.

Product overview

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company with a single-product pipeline focused on BXQ-350, a first-in-class sphingolipid metabolism modulator. BXQ-350 is a biologic composed of Saposin C (an 80-amino acid protein) embedded in DOPS (Dioleoyl Phosphatidylserine) vesicles. The company is advancing BXQ-350 across multiple clinical programs including Phase 1b/2 studies in metastatic colorectal cancer (mCRC) and proof-of-concept trials for chemotherapy-induced peripheral neuropathy (CIPN), with emerging evidence in neurological diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• BXQ-350 First-in-class biologic composed of Saposin C (SapC), an 80-amino-acid sphingolipid activator protein, embedded in DOPS (Dioleoyl Phosphatidylserine) vesicles. It modulates sphingolipid metabolism—lowering Sphingosine-1-Phosphate (S1P) and increasing ceramide—to create an anti-tumor microenvironment, repolarize macrophages toward M1, inhibit MDSCs, activate NK and T cells, and provide neuroprotective effects against chemotherapy-induced peripheral neuropathy (CIPN). Currently being investigated for metastatic colorectal cancer (mCRC), glioblastoma (GBM), pediatric DIPG/DMG, and CIPN.

Quantifiable outcome

• In Phase 1b/2a mCRC study, BXQ-350 + FOLFOX + bevacizumab achieved efficacy outcomes at or above SOC alone in a poor-prognosis patient population, with patients attaining higher cumulative oxaliplatin dosing, fewer dose reductions, and fewer early terminations.
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Cancer Support CommunitycoreStrategic or Co-development PartnerBexion Pharmaceuticals is proud to collaborate with patient organizations to better support the oncology community. The company actively engages with advocacy partners to ensure priorities are aligned with those of cancer patients and their families.
• LifeSciKYcoreStrategic or Co-development PartnerLifeSciKY is a shared laboratory facility in Covington, KY that officially opened in September 2025 to support early-stage biotech, biopharma, medical device, and health technology startups. Bexion Pharmaceuticals is anchored at LifeSciKY as a key tenant and industry leader, alongside CARTx, in the growing Covington life sciences innovation hub.
• Thermo Fisher ScientificminorStrategic or Co-development PartnerThermo Fisher Scientific, an industry leader in life sciences and laboratory equipment, is set to join the Covington, Kentucky life sciences ecosystem anchored by LifeSciKY. While not yet formally partnered, Thermo Fisher's planned presence in the ecosystem would complement companies like Bexion Pharmaceuticals operating in the same innovation hub.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mirati Therapeutics: Clinical-stage oncology biotech that developed targeted cancer therapeutics (e.g., KRAZATI) for solid tumors. Comparable as a small-cap private/early-public oncology company advancing a single differentiated biologic through Phase 1b/2 trials in solid tumors including colorectal.
• Erasca: Clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway in solid tumors. Directly comparable as a single-asset-focused clinical-stage biotech advancing novel mechanism oncology drugs through Phase 1b/2 in colorectal and other solid tumors.
• Relay Therapeutics: Clinical-stage precision medicine company developing targeted oncology therapies using motion-based drug design. Comparable as a clinical-stage biotech with a differentiated mechanism-of-action platform advancing assets in colorectal and other solid tumors.
• Theseus Pharmaceuticals: Clinical-stage oncology biotech developing kinase inhibitors for solid tumors. Comparable as a small clinical-stage company advancing a novel-mechanism oncology asset through early-phase trials with a focus on overcoming treatment resistance.
• Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting the chromatin regulatory system in oncology. Comparable as a clinical-stage company with a novel biologic platform addressing fundamental cancer biology pathways across multiple solid tumor indications.
• Humanigen: Clinical-stage immuno-oncology company developing lenzilumab and other biologics for cancer and inflammatory conditions. Comparable as a small clinical-stage biotech where Tariq Arshad (Bexion's current CMO) previously served as CMO.
• Kronos Bio: Clinical-stage biotech developing oncology therapeutics targeting dysregulated transcription factors. Comparable as a clinical-stage company with a single-platform approach addressing fundamental cancer biology through novel small molecule and biologic mechanisms.

Broad incumbents

• Merck & Co. Large pharmaceutical company with established oncology franchise including Keytruda and a broad CRC pipeline. Comparable as a broad incumbent in oncology that competes in mCRC and could be a potential acquirer or combination partner for BXQ-350.
• Bristol-Myers Squibb: Major oncology player with Opdivo, Yervoy, and colorectal cancer development programs. Comparable as a broad incumbent in immuno-oncology and mCRC; potential strategic acquirer given overlapping interest in tumor microenvironment modulation.

Emerging players

• Metys Pharmaceuticals: Emerging clinical-stage company developing treatments for chemotherapy-induced peripheral neuropathy (CIPN). Directly comparable as a peer developing therapeutics for the same CIPN indication Bexion is targeting with BXQ-350's CIPN proof-of-concept program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bexion-pharmaceuticals
• Xx.com/bexionpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bexion Pharmaceuticals